AI model that checks for skin cancer shows promise

Scientists in the East of England have developed a way of using artificial intelligence to check for skin cancer, with the AI tool outperforming existing methods in a new study.

Researchers from Anglia Ruskin University, Check4Cancer, University of Essex and Addenbrooke’s Hospital worked on the AI model which was trained on data from 53,601 skin lesions from 25,105 patients.

In this study, researchers used machine learning and combination theory to distill 22 clinical features down to the most important that predict if a skin lesion might be suspicious or not. These features include: whether the lesion has recently changed size, color or shape; whether the lesion was pink or inflamed; and hair color at age 15. The findings are published in the journal Scientific Reports.

Researchers applied proportional weighting to these features to create the new C4C Risk Score which has an accuracy of 69%. In the study, it significantly outperformed existing methods such as 7PCL (62%) and Williams score (60%).

Some of the new risk factors they discovered, such as lesion age, pinkness, and hair color, were important for all types of skin cancer but were not included in the older methods, which only focused on melanoma, a specific type of skin cancer.

Professor Gordon Wishart, Visiting Professor of Cancer Surgery at Anglia Ruskin University and Chief Medical Officer at Check4Cancer, said, “This study shows the importance of using clinical data in skin lesion classification, which should help to improve the detection of skin cancer.

“Our new AI model, which combines the C4C risk score together with skin lesion images, could lead to a reduction in the need for patient referrals for biopsies, shorter waiting times for skin cancer diagnosis and treatment, and improved outcomes for patients.”

Consultant Plastic Surgeon Per Hall, who recently retired from Addenbrooke’s, said, “The added value that this paper brings is the ability to help identify patients whose skin lesions are suspicious enough to justify onward referral for face-to-face analysis.

“Emphasis in the past has been on pigmented lesions and melanoma but other things grow on the skin that need sorting out such as basal cell carcinomas and squamous cell carcinomas.

“The NHS is deluged with referrals for skin lesion analysis—the vast majority are in fact innocent. This work is geared towards sifting out lesions that are potentially serious and identifying those patients whose skin is more prone to developing cancers so they can be seen quickly.”

It is hoped that regulatory approval for the AI model can be given in 2025.